1. In Vivo
  2. >>Global Vision

Amdipharm: From Pharmacist to Pharma Firm

 
• By Melanie Senior

Amdipharm was set up in April 2003 to find and market niche products in areas of real clinical need, considered too small-or unsexy-for larger players. Wholly-owned by UK-based distributor and wholesaler Waymade Healthcare, which started out as a chain of pharmacies, Amdipharm's management reckons that the group's experience across the drug distribution chain, particularly at the buyer's end, and its proven deal making prowess, will help it achieve its aim of becoming a successful European pharma company.

The latest trend in the Big Pharma industry, given the dearth of new blockbusters coming through R&D, may be to go specialist, but it's still all relative. Pfizer Inc. 's co-promotion of Merck Serono SA 's interferon-beta drug Rebif for multiple sclerosis still involves a $550 million drug; Roche sells cancer products worth several hundred million in annual sales. These products may never be blockbusters, but they're still large enough to leave plenty of far smaller drugs off the bottom of pharma's priority list. Consolidation—both between Big Pharma and with biotechs—will likely continue to throw up stray compounds, or drugs which must be sold to satisfy increasingly stringent competition laws.

All of which endorses the strategy of firms like Amdipharm Mercury Ltd. , a wholly owned subsidiary of UK...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.